BOT 0.00% 31.5¢ botanix pharmaceuticals ltd

I believe you're overanalysing this. firstly, to be deemed a...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 573 Posts.
    lightbulb Created with Sketch. 211
    I believe you're overanalysing this.



    firstly, to be deemed a "competitive" product you'd assume they're marketed and commercially produced for treatments.



    secondly, why must the question be the quality of OTC products? the percentages? if they have 10%, 15%, 40%, CBD,it's irrelevant. OTC products aren't completely dependent on CBD either. it's a combination of factors, that's one (active) ingredient you're targeting. if one product have optimised their results with 10% CBD and the other 60%, it doesn't matter. you don't fix concentrations to draw relevant comparisons on effectiveness or target concentration to the superficial skin layers.



    thirdly ... why? they have 3 separate products for this.



    fourthly ... NO. OTC products are relevant seeing that's the active ingredient. that was the point of the 3rd party analysis.



    Criticism is obviously welcome. just don't think your points are completely accurate .... good thoughts nevertheless!
    Last edited by zabba198: 27/02/19
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
31.5¢
Change
0.000(0.00%)
Mkt cap ! $707.4M
Open High Low Value Volume
31.5¢ 32.5¢ 30.5¢ $1.502M 4.765M

Buyers (Bids)

No. Vol. Price($)
4 189068 31.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 535424 6
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.